Orforglipron

Status

FDA-approved. Approved in the US on 1 April 2026 under FDA's National Priority Voucher program, and authorised by the UK MHRA on 10 August 2026. It is the first oral small-molecule GLP-1 agonist to reach approval.

What it is

Not a peptide at all — a small molecule taken as a daily pill that activates the same GLP-1 receptor the injected peptides use. No refrigeration, no injection, and a manufacturing process closer to ordinary pharmaceuticals.

What published research measured

The ACHIEVE program studied weight management and type 2 diabetes, including a cardiovascular safety readout (ACHIEVE-4).

Source

FDA/MHRA announcements; ACHIEVE trial program

Sources

• Half-life source for Orforglipron
• Foundayo (orforglipron) tablets label (revised 07/2026)
• Foundayo tablets (once daily) prescribing information